PTO/SB/08 (11-07)

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | Con | nplete if Known |
|--------------|-------------|------------|---------|------------------------|-------------------------|
| Substitute f | or form 144 | 9/PTO | | Application Number | 10/537,756 |
| INFORM | MATION | DISC | LOSURE | Filing Date | October 25, 2005 |
| STATE | MENT B | Y APP | LICANT | First Named Inventor | David John Haydon |
| (Use a | s many shee | ets as nee | essary) | Art Unit | 1652 |
| | | | | Examiner Name | Iqbal Hossain Chowdhury |
| Sheet | 1 | Of | 4 | Attorney Docket Number | 35813-709.831 |

| | | U.S. PA | TENT DOC | UMENTS | |
|-----------------------|--------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | 11. | US-6,747,137 | 062004 | Weinstock et al. | |

| | | FOREIGN | PATENT DO | OCUMENTS | | |
|-----------------------|-------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. | Foreign Patent Document Country Code ³ – Number ⁶ – Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | 12. | WO-2002-02784 | 01-10-2002 | Anadys Pharmaceuticals | | |
| | 13. | WO-2001-60975 | 08-23-2001 | Boone et al. | | |

| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|-----------------------|--------------|---|----------------|
| | 14. | Aebi et al., "Isolation of a Temperature-sensitive Mutant with an Altered tRNA Nucleotidyltransferase and Cloning of the Gene Encoding tRNA Nucleotidyltransferase in the Yeast Saccharomyces cerevisiae," J. Biol. Chem. 265:16216-16220 (1990) | |
| | 15. | Antifungal definition from Merriam-Webster Online Dictionary 11/08/06 | |
| | 16. | Backen et al., "Evaluation of the CaMAL2 promoter for regulated expression of genes in Candida albicans," Yeast 16:1121-1129 (2000) | |
| | 17. | Bruno et al., "Large-scale gene function analysis in Candida albicans," Trends Microbiol. 12:157-161 (2004) | |
| | 18. | Chen et al., "Cytoplasmic and Mitochondrial tRNA Nucleotidyltransferase Activities Are Derived from the Same Gene in the Yeast Saccharomyces cerevisiae," J. Biol. Chem. 267:14879-14883 (1992) | |

| Examiner | Date | | 1 |
|--|--|---|---|
| Signature | Considered | | ı |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance | with MPEP 609. Draw line through o | sitution if not in conformance and not considered. Include copy | |
| of this form with next communication to applicant 'Applicant's unique citation designation | on number (optional) ² See Kinds Cod | es of USPTO Patent Documents at www.uspto.gov.or MPEP | |
| 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST | For Japanese patent documents, | the indication of the year of the reign of the Emperor must | |
| precede the serial number of the patent document. Kind of document by the appropriate s | ymbols as indicated on the document u | under WIPO Standard ST 16 if possible "Applicant is to place a | |
| check mark here if English language Translation is attached. | | | |
| | | | |

clock max her if English Ingregar Translation is statisted.

17 Tel. 97 and 198. The information is required by 27 CFR 197 and 198. The information is required to obtain or retain a basefit by the public which is to file (and by the USFTO to process) an explosions. Confidentially is governed by 35 U.S.C. 123 and 37 CFR 1.14. This collection is estimated to take 2 hours to complexe, including gathering, preparing, and substrating the complexed publication of the collection of the collection is estimated to take 2 hours to complexe, detailing gathering, preparing, and substrating the controlled publication of the collection of the colle

PTO/SB/08 (11-07)

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | Cor | nplete if Known |
|--------------|-------------|-----------|---------|------------------------|-------------------------|
| Substitute f | or form 144 | 9/PTO | | Application Number | 10/537,756 |
| INFORM | ATION | DISCI | OSURE | Filing Date | October 25, 2005 |
| | MENT BY | | | First Named Inventor | David John Haydon |
| (Use as | s many shee | ts as nec | essary) | Art Unit | 1652 |
| | | | | Examiner Name | Iqbal Hossain Chowdhury |
| Sheet | 2 | Of | 4 | Attorney Docket Number | 35813-709.831 |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T' |
| | 19. | Chen et al., "Purification and Properties of Yeast ATP (CTP):tRNA Necleotidyltransferase from Wild Type and Overproducing Cells," J. Biol. Chem. 265:16221-16224 (1990) | |
| | 20. | Cho et al., "Use of nucleotide analogs by class I and class II CCA-adding enzymes (IRNA nucleotidyltranserase): Deciphering the basis for nucleotide selection," RNA 9:970-981 (2003) | |
| | 21. | De Backer et al., "Genomic profiling of the response of Candida albicans to irraconazole treatment using a DNA microarray," Antimicrobial Agents + Chemother. 45(6):1660-1670 (2001) | |
| | 22. | De Backer et al., "Recent developments in molecular genetics of Candida albicans," Ann. Rev. Microbiology 54:463-498 (2000) | |
| | 23. | De Backer et al., "An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans," Nature Biotech. 19(3):235-241 (2001) | |
| | 24. | De Backer et al., "RNA-mediated gene silencing in non-pathogenic and pathogenic fungi," Curr. Op. Microbiol. 5(3):323-329 (2002) | |
| | 25. | Deng et al., "Isolation and nucleotide sequence of a gene encoding tRNA nucleotidyltransferase from Kluyveromyces lactis," Yeast 16:945-952 (2000) | |
| | 26. | Ghannoum et al., "Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance," Clin. Microbiol. Rev. 12(4):501-517 (1999) | |
| | 27. | Glaever et al., "Functional profiling of the Saccharomyces cerevisiae genome," Nature 418(6896): 387-391 (2002) | |
| | 28. | Hanic-Joyce, et al., "Characterization of a gene encoding tRNA nucleotidyltransferase | |

| Examiner | | Date | |
|------------|---|---------------------|---|
| Signature | | Considered | |
| *EXAMINER: | Initial if reference considered, whether or not citation is in conformance with MPEP 609. | Draw line through o | citation if not in conformance and not considered. Include copy |

^{**}EAANINES! Install reference considered, whether or not cisation is in conformance with MFEP 600. Drew line through cisation first in conformance and not considered include copy of the form with non-communication to applicable. "Application shape cisation designation conformance and not considered include copy of the first office loss trends the consensus by the non-cisation conformation and the consensus by the non-cisation conformation and the consensus of t

-2-

check must here it lengths language [Institution in attitudes] and LISA. The information is required to define or retain a beautify to be public which is no file (and by the USETTO to process) have included in a continuous an executive by 10 CM or 10 cm 1

PTO/SB/08 (11-07) Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | Cor | nplete if Known |
|--------------|-------------|----------|----------|------------------------|-------------------------|
| Substitute f | or form 144 | 9/PTO | | Application Number | 10/537,756 |
| INFORM | IATION | DISC | LOSURE | Filing Date | October 25, 2005 |
| STATE | MENT BY | APP | LICANT | First Named Inventor | David John Haydon |
| (Use a: | many shee | ts as ne | cessary) | Art Unit | 1652 |
| | | | | Examiner Name | Iqbal Hossain Chowdhury |
| Sheet | 3 | Of | 4 | Attorney Docket Number | 35813-709.831 |

| | | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | |
|-----------------------|--------------|---|---|
| Examiner Initials* | Cite No.1 | item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| | | from Candida glabrata," Yeast 19(16):1399-1411 (2002) | |
| | 29. | Invitrogen Product Catalog 2000:pp.viii and 79 | |
| | 30. | Kroger et al., "Reversible Inactivation of IRNA Nucleotidyltransferase from Baker's Yeast by IRNA ^{nec} Containing Iodoacetamide-Alkylated 2-Thiocytidine in Normal and Additional Positions," Eur. J. Biochem. 95:341-348(1970) | |
| | 31. | Navarro et al., "Characteristics of the Inhibition and Metabolic Inactivation of the Yeast tRNA Nucelotidyltransferase," Italian J. Biochem. 40:295-303 (1991) | |
| | 32. | Onishi et al., "Discovery of Novel Antifungal (1,3)-β-D-Glucan Synthase Inhibitors," Antimicrobial Agents and Chemotherapy 44(2):368-377 (2000) | |
| | 33. | Peltz et al., "A Mutation in the tRNA Nucleotidyltransferase Gene Promotes Stabilization of mRNAs in Saccharomyces cerevisiae," Mol. Cell Biol. 12:5778-5784 (1992) | |
| | 34. | Roemer et al., "Large-scale essential gene identification in Candida albicans and application to antifungal drug discovery," Mol. Microbiol. 50(1):167-181 (2003) | |
| | 35. | Song et al, "RAM2: an essential gene in the prenylation pathway of Candida albicans," Microbiol. 149:219-259 (2003) | |
| | 36. | Spaltmann et al., "Computer-aided target selection-prioritizing targets for antifungal drug discovery," Drug Discovery Today, 4: 17-26 (1999) | |
| | 37. | Sternbach et al., "Afinity Labelling of tRNA Nucleotidyltransferase from Baker's Yeast with tRNA Phe Modified on the 3'-Terminus," Eur. J. Biochem. 67:215-221 (1976) | |
| | 38. | Vesses et al., "ABG1, a Novel and Essential Candida albicans Gene Encoding a Vauolar Protein Involved in Cytokinesis and Hyphal Branching," Eukaryotic Cell 4(6):1088-1101 (2005) | |

| Signature | Considered | |
|--|---|------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEI | | |
| of this form with next communication to analyzant. Analizant's unique citation designation number (s | (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov.or. | MPEP |

of this form with next communication to applicase. *Applicant's unique clause a designation number (optional). *See Kalia Codes of USPTO Pares Decuments as www upon gor or MFIP*

Ol 10. *Earn Office is based and electrone, by the work-letter odd, "To Palments pearle of Letters," the To Palments pearle of Letters and the part of the reg part of part of the part of

- 3 -

PTO/SB/08 (11-07)

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | Complete if Known | | |
|---|------------|---------|---------|------------------------|-------------------------|--|--|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE | | | | Application Number | 10/537,756 | | |
| | | | | Filing Date | October 25, 2005 | | |
| STATEMENT BY APPLICANT | | | LICANT | First Named Inventor | David John Haydon | | |
| (Use as | many sheet | s as ne | essary) | Art Unit | 1652 | | |
| | | | | Examiner Name | Iqbal Hossain Chowdhury | | |
| Sheet | 4 | Of | 4 | Attorney Docket Number | 35813-709.831 | | |

| | | lude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | | |
|-----------------------|--------------|--|---|--|
| Examiner Initials* | Cite No.1 | item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Т | |
| | 39. | Weiner, Alan, "tRNA Maturation: RNA Polymerization without a Nucleic Acid | П | |
| | | Template," Curr. Biol. 14:R883-R885 (2004) | | |
| | 40. | Wolfe et al., "Mechanisms Leading to and the Consequences of Altering the Normal | | |
| | | Distribution of ATP(CTP):tRNA Nucelotidyltransferase in Yeast," J. Biol. Chem. 271:4679-4686 (1996) | | |
| | 41. | Wood et al., "The genome sequence of Schizosaccharomyces pombe," Nature 415(6874): 871-880 (2002) | | |
| | 42. | Yue et al., "The CCA-adding Enzyme Has a Single Active Site," J. Biol. Chem. 273:29693-29700 (1998) | | |

| - [| Examiner | Date | |
|-----|-----------|------------|--|
| ı | Signature | Considered | |

Segmentary

EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 900. Draw line through classion if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unspec cutation designation number (optional). "See Kinds Code or USF ID Parent Documents at www upper gov or MPEP 900. The transpect performance and the season the document by the rew-letter code (MPIO Standard ST.) "The Supamore parts of counterms, the indication of the year of the rigo of the performance performance and the performance of the parent counters." Kind of document by the appropriate symbols as indicated on the document under WIFO Standard ST. 16 if possible. "Applicant is to place a clock mark her if English dangange Translation is nateded."

ORCE TEXT OF It Engines managing interactions interaction and 1.98. The information is required to obtain or retain a beautif by the public which is to Efficiently by the USETO to precent and the interaction of the public which is to Efficiently by the USETO to precent and the interaction of the public which is to Efficiently the USETO to precent and the interaction of the public in public and the otherwise the complete aggleration form to the USETO. Time will vary depending upon the individual case. Any comments on the mount of time you require to complete this form native suggestions for consisting this branch, about the secret to the Complete this form made vaugestions for consisting this branch, about the secret to the Complete this form made vaugestions for robusting this branch, about the secret to the Complete this form made vaugestions for robusting this branch, about the secret to the Complete this form made vaugestions for robusting this branch, about the secret to the Complete this form made vaugestions for robusting this branch, about the secret to the Complete this form made vaugestions for robusting this production. The complete this form made vaugestions for robusting this production of the production of the complete this form made vaugestions for robusting this production. The production of the production o